Company Overview
About OpenBiome
OpenBiome is a Cambridge, Massachusetts-based nonprofit health research organization — backed by Y Combinator (W20) — that operated as the largest distributor of fecal microbiota transplant (FMT) products in the United States for over a decade, providing investigational FMT therapy to thousands of patients with recurrent Clostridioides difficile (C. diff) infection while accelerating research on human microbiome therapeutics. Founded in 2012, OpenBiome suspended FMT distribution as of December 31, 2024, following FDA regulatory changes that ended enforcement discretion for investigational FMT, and submitted an IND Phase 2 protocol application in November 2024 to pursue the FDA-approved clinical pathway for continued microbiome therapeutic development.
Business Model & Competitive Advantage
OpenBiome's FMT distribution model addressed the critical gap between proven clinical efficacy and patient access for one of medicine's most evidence-backed interventions: C. diff infection affects 500,000 Americans annually with 30,000+ deaths, and recurrent C. diff (failing 2+ antibiotic courses) responds to FMT at 80-90% cure rates versus 30-40% for additional antibiotics — but FMT requires a screened, tested donor stool sample that most hospital systems cannot safely source independently. OpenBiome's centralized manufacturing model (rigorous donor screening for pathogens, standardized processing for safety and efficacy, distribution to 1,000+ hospitals and outpatient centers) enabled physicians nationwide to offer FMT under FDA enforcement discretion while building the clinical evidence base that informed the FDA's eventual approval pathway. The decade of distribution data and outcomes collection made OpenBiome the world's largest clinical FMT dataset.
Competitive Landscape 2025–2026
In 2025, OpenBiome navigates the post-enforcement-discretion regulatory transition alongside commercial microbiome therapeutic companies Seres Therapeutics (NASDAQ: MCRB, VOWST approved for C. diff, FDA-approved FMT-derived therapy) and Ferring Pharmaceuticals (REBYOTA, FDA-approved live biotherapeutic for C. diff). The FDA's transition from enforcement discretion to formal drug approval pathways for FMT-derived products (driven by safety concerns about serious adverse events in immunocompromised patients) has reorganized the FMT landscape around IND-approved clinical trials and commercial biologics. OpenBiome's IND Phase 2 submission positions the nonprofit to continue contributing to microbiome research within the formal regulatory framework. The 2025 strategy focuses on completing the Phase 2 clinical trial for the IND-approved FMT program, building the research partnerships with academic medical centers for microbiome science advancement, and advocating for patient access pathways during the transition from investigational FMT to commercially approved microbiome therapeutics.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
OpenBiome is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Not So Random Others
Yoneda Labs
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit
Decoda Health
Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap
Fortuna Health
Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowi
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
AbbVie
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp
Compare OpenBiome with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from OpenBiome? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim OpenBiome Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention OpenBiome vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →